| 喻嫦娥,余忠华.端粒酶抑制剂GRN163L在肿瘤治疗中的研究进展[J].肿瘤学杂志,2013,19(3):231-234. |
| 端粒酶抑制剂GRN163L在肿瘤治疗中的研究进展 |
| Progress in Telomerase Inhibitor GRN163L in the Treatment for Cancer |
| 投稿时间：2012-09-17 |
| DOI：10.11735/j.issn.1671-170X.2013.03.B2012468 |
|
 |
| 中文关键词: 端粒酶 GRN163L 恶性肿瘤 |
| 英文关键词:telomerase GRN163L tumor |
| 基金项目: |
|
| 摘要点击次数: 1994 |
| 全文下载次数: 1420 |
| 中文摘要: |
| 摘 要:GRN163L是一种针对hTR (端粒酶 RNA)的反义核苷酸药物，它能够抑制端粒酶的活性，引起肿瘤染色体末端端粒长度的不断缩短，诱导肿瘤细胞停止分裂。作为针对hTR基因靶向治疗的前沿药物，GRN163L逐渐成为临床研究的热点。全文拟从端粒及端粒酶、GRN163L的理化性质、生物学功能及肿瘤治疗的相关研究进展作一综述。 |
| 英文摘要: |
| Abstract: GRN163L (Geron Presentations on Imetelstat) is an antisense nucleotide drugs armming at hTR (telomerase RNA)，which can inhibit the activity of telomerase，cause telomere length of tumor chromosome ends constantly shortened and induce tumor cells to stop splitting. As a therapy forefront drug targetting the hTR gene，GRN163L gradually become the focus of clinical research. This paper will expound telomeres and telomerase，physical and chemical properties of GRN163L，biological function of GRN163L and research progress of tumor therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|